Arcus Biosciences, Inc.
General ticker "RCUS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.1B (TTM average)
Arcus Biosciences, Inc. follows the US Stock Market performance with the rate: 57.6%.
Estimated limits based on current volatility of 2.4%: low 26.35$, high 27.66$
Factors to consider:
- Total employees count: 601 (-4.1%) as of 2025
- Top business risk factors: Limited operating history, Inability to raise capital, Clinical trial failure, Regulatory and compliance, Manufacturing supply issues
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [14.38$, 32.23$]
- 2026-12-31 to 2027-12-31 estimated range: [10.69$, 24.92$]
Financial Metrics affecting the RCUS estimates:
- Negative: with PPE of -6.8 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 2.69 > -0.60
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term RCUS quotes
Long-term RCUS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $117.00MM | $258.00MM | $247.00MM |
| Operating Expenses | $457.00MM | $588.00MM | $633.00MM |
| Operating Income | $-340.00MM | $-330.00MM | $-386.00MM |
| Non-Operating Income | $39.00MM | $48.00MM | $33.00MM |
| Interest Expense | $0.00MM | $4.00MM | $8.00MM |
| R&D Expense | $340.00MM | $448.00MM | $523.00MM |
| Income(Loss) | $-301.00MM | $-282.00MM | $-353.00MM |
| Taxes | $6.00MM | $1.00MM | $0.00MM |
| Net Income(Loss)* | $-307.00MM | $-283.00MM | $-353.00MM |
| Stockholders Equity | $462.00MM | $485.00MM | $631.00MM |
| Assets | $1,095.00MM | $1,150.00MM | $1,139.00MM |
| Operating Cash Flow | $-306.00MM | $-170.00MM | $-482.00MM |
| Capital expenditure | $24.00MM | $6.00MM | $2.00MM |
| Investing Cash Flow | $194.00MM | $-84.00MM | $66.00MM |
| Financing Cash Flow | $33.00MM | $277.00MM | $488.00MM |
| Earnings Per Share** | $-4.15 | $-3.14 | $-3.29 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.